Concord Medical Services AI Stock Analysis
Want to see CCM full AI Analyst Report?
Concord Medical Services (CCM) AI Stock Analysis
Concord Medical Services
(NYSE:CCM)
Concord Medical Services scores near the bottom of the range, driven primarily by severe financial distress: negative stockholders' equity of RMB -2.1B, RMB 3.63B of debt against a small revenue base, six straight years of losses, and persistent negative free cash flow. Encouraging 2025 trends — 26% revenue growth, a return to positive gross profit, and materially reduced cash burn — provide only modest offset against going-concern risk. Technicals reinforce the caution, with the stock trading below all major moving averages and negative MACD momentum, though oversold RSI and Stochastic readings hint at potential short-term stabilization. Valuation offers no anchor given negative earnings, no dividend, and negative book value. This remains a highly speculative, distressed situation.
Concord Medical Services (CCM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $522.45K
- Dividend Yield
- ―
- Average Volume (3M)
- 23.67K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.01
- Revenue Growth
- 20.26%
- EPS Growth
- 69.68%
- Country
- US
- Employees
- 610
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Concord Medical Services Business Overview & Revenue Model
Company Description
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services includ...
How the Company Makes Money
CCM makes money primarily by delivering and managing oncology-focused clinical services, with revenues historically tied to patient volumes and the utilization of high-end equipment used in cancer diagnosis and treatment. Key revenue streams include:...
Concord Medical Services Financial Statement Overview
Summary
All three statements point to severe distress. Six consecutive years of net losses (cumulative RMB 1.77B), negative gross margins in four of the last five years, and 2025 EBITDA of RMB -72M leave the company far from breakeven despite 26% revenue growth and a marginally positive gross profit. The balance sheet is the weakest link: stockholders' equity is deeply negative at RMB -2.1B against RMB 3.63B of debt (nearly 8x annual revenue), making the company technically insolvent on a book basis. Cash flow has been negative every year since 2020, with 2025 operating cash flow of RMB -202M and free cash flow of RMB -293M, though burn did moderate meaningfully from 2024 levels. The directional improvements are real but insufficient to offset elevated going-concern, restructuring, and dilution risk.
Income Statement
8Very NegativeBalance Sheet
4Very NegativeCash Flow
6Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 585.66M | 460.51M | 383.96M | 537.40M | 472.08M | 485.63M |
| Gross Profit | 40.31M | 25.82M | -79.16M | -76.61M | -152.41M | -56.90M |
| EBITDA | -75.84M | -71.77M | -345.62M | -334.53M | -392.23M | -354.24M |
| Net Income | -124.44M | -92.81M | -308.24M | -297.66M | -489.66M | -271.43M |
Balance Sheet | ||||||
| Total Assets | 6.55B | 6.55B | 6.73B | 6.05B | 6.00B | 6.23B |
| Cash, Cash Equivalents and Short-Term Investments | 297.79M | 297.79M | 350.85M | 58.14M | 158.28M | 157.39M |
| Total Debt | 3.63B | 3.63B | 3.93B | 3.30B | 3.24B | 2.73B |
| Total Liabilities | 4.70B | 4.70B | 5.11B | 4.31B | 3.99B | 3.49B |
| Stockholders Equity | -2.10B | -2.10B | -2.28B | -2.12B | -1.86B | -1.37B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -293.16M | -808.58M | -392.17M | -600.47M | -1.12B |
| Operating Cash Flow | 0 | -201.82M | -397.75M | -276.47M | -216.69M | -359.31M |
| Investing Cash Flow | 0 | 53.97M | -593.44M | -47.68M | -118.79M | -565.98M |
| Financing Cash Flow | 0 | 197.23M | 1.15B | 257.65M | 383.09M | 642.45M |
Concord Medical Services Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Negative. The current price of 3.61 is below the 20-day moving average (MA) of 3.67, below the 50-day MA of 3.63, and below the 200-day MA of 4.17, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.56 is Neutral, neither overbought nor oversold. The STOCH value of 61.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCM.
Concord Medical Services Risk Analysis
Concord Medical Services disclosed 78 risk factors in its most recent earnings report. Concord Medical Services reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksConcord Medical Services Peers Comparison
Overall Rating
JYNT59Neutral
CCEL53Neutral
AMS50Neutral
PIII48Neutral
DCGO40Underperform
CCM39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 59Neutral | $91.03M | 33.32 | 19.28% | ― | 7.86% | 55.56% | |
| 53Neutral | $33.62M | -18.60 | 15.84% | ― | -1.96% | -314.41% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $6.88M | -3.03 | -10.19% | ― | 4.90% | -3.41% | |
| 48Neutral | $15.61M | -0.09 | 171.75% | ― | 7.54% | 42.43% | |
| 40Underperform | $17.37M | -0.09 | -144.87% | ― | -19.22% | -254.04% | |
| 39Underperform | $15.67M | -0.03 | 5.16% | ― | 20.26% | 69.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CCM | Concord Medical Services | 3.61 | -0.36 | -9.07% | |
| AMS | American Shared Hospital Services | 1.03 | -1.04 | -50.24% | |
| JYNT | Joint Corp | 6.65 | -1.55 | -18.90% | |
| CCEL | Cryo-Cell International | 4.17 | 0.15 | 3.83% | |
| DCGO | DocGo, Inc. | 0.17 | -0.70 | -80.05% | |
| PIII | P3 Health Partners Inc. | 2.15 | -3.72 | -63.37% |
Concord Medical Services Corporate Events
Concord Medical Names Interim CFO as Wei Jiang Steps Down
Concord Medical announced that chief financial officer Wei Jiang stepped down from his role effective June 30, 2026, to concentrate on the business and operations of Concord Healthcare Group, the company’s Hong Kong-listed subsidiary. The company emp...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026
